Primary-Prevention Data Should Boost Uptake Of Amgen’s Repatha

Tough Competition Looms

Close up of Amgen sign at its headquarters in Thousand Oaks, California, USA
Amgen announced results from the Phase III VESALIUS-CV trial of Repatha. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

More from R&D